Alpha 2.0
Login Register
» Articles » PMID: 39687390

Long-term Dupilumab Efficacy in Type 2 Asthma Regardless of Baseline Characteristics

Overview
Journal ERJ Open Res
Specialty Pulmonary Medicine
Date 2024 Dec 17
PMID 39687390
Authors
Michael E Wechsler
Linda Rogers
G Walter Canonica
Arnaud Bourdin
Arman Altincatal
Megan Hardin
Xavier Soler
Paul J Rowe
Yamo Deniz
Harry Sacks
Juby A Jacob-Nara
Affiliations
Soon will be listed here.
Abstract

https://bit.ly/3XSwX62.

References
1.
Castro M, Corren J, Pavord I, Maspero J, Wenzel S, Rabe K . Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018; 378(26):2486-2496. DOI: 10.1056/NEJMoa1804092. View
2.
Murphy A, Macdonald L, Stevens S, Karow M, Dore A, Pobursky K . Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014; 111(14):5153-8. PMC: 3986188. DOI: 10.1073/pnas.1324022111. View
3.
Maspero J, Cardona G, Schonffeldt P, Tolcachier A, Gonzalez-Diaz S, Yanez A . Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study. J Asthma. 2022; 60(5):981-990. DOI: 10.1080/02770903.2022.2115927. View
4.
Wechsler M, Ford L, Maspero J, Pavord I, Papi A, Bourdin A . Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2021; 10(1):11-25. DOI: 10.1016/S2213-2600(21)00322-2. View
5.
Fahy J . Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol. 2014; 15(1):57-65. PMC: 4390063. DOI: 10.1038/nri3786. View